comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 15:28:47 - browse：6456

Have you ever taken phenylephrine for a stuffed-up nose and then felt better? If so, you might have been perplexed when Food and Drug Administration experts recently said that that the drug — which is in some versions of DayQuil, Sudafed, and other medicines — is no more effective than a placebo.

But to Michael H. Bernstein, an assistant professor of diagnostic imaging at the Warren Alpert Medical School of Brown University, it all makes sense. Bernstein says that “no better than a placebo” still means that it works, sort of. “If we expect to feel better, then we probably will,” he told me. And that complicates the idea of what medical treatment “works.”

On this episode of the “First Opinion Podcast,” we discuss the placebo effect and its counterpart, the “nocebo effect” — if you tell patients something will make them feel worse, it generally comes true. “You’re better off hearing from a doctor something to the effect of 3 out of 4 patients who take this drug have no side effects at all versus 25% of people who take this drug do get side effects,” he said.

Bernstein also shared the delightful story of how he got into the “medical expectations” field, which started with an experiment in which he had to convince underage students that they were drinking alcohol when they weren’t.

Our conversation was based on a First Opinion Bernstein recently wrote with Grayson L. Baird, “Phenylephrine is no better than a placebo. What if that’s still better than nothing?”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Alkermes shareholders re
Next article： What to know about Virgin Galactic's 1st mission taking paying customers to space

WSS

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Why failed clinical trials don’t always spell doom for a new drug

focus

comprehensive

entertainment

ChatGPT in medicine: STAT answers readers' burning questions

Naloxone nonprofit donates 200,000 doses after FDA approval

New air purifier tech could be key to improving indoor air quality

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

Jerome Adams on the need for new antivirals for Covid

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

Alkermes shareholders re

An Ebola outbreak presents a new mystery involving children

Alkermes shareholders re

Wegovy’s successful heart trial raises vital question about weight loss

hotspot

Travel bans should be based on evidence, not politics or fear

Naloxone nonprofit donates 200,000 doses after FDA approval

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Astronauts get first look at the spacecraft that will fly them around the moon

Discs beat pads, tampons for heavy menstrual flow, new study shows

An Ebola outbreak presents a new mystery involving children

leisure time

focus

leisure time

leisure time